Donald Halbert this week was named executive vice president of research and development for Iconix Pharmaceuticals. Halbert was director of genomics, proteomics, and bioinformatics in the global pharmaceutical research and development group of Abbott Laboratories. Additionally, Halbert directed Abbott's toxicogenomics program and oversaw the scientific advisory committee that directed a collaboration between Abbott and Iconix that was initiated in December 2003. Before joining Abbott, Halbert was an executive with Becton Dickinson.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.